TY - JOUR T1 - Exploring the correlation between the fibrosis-4 score and quantitative ultrasonographic liver fat measurements in metabolic dysfunction-associated steatotic liver disease AU - Karabörk Kılıç, Atiye Cenay AU - Şendur, Halit Nahit AU - Aşiret, Emre AU - Özbaş, Cansu AU - Şendur, Aylin Billur AU - Cerit, Mahinur AU - Oktar, Suna PY - 2026 DA - March Y2 - 2026 DO - 10.47582/jompac.1871085 JF - Journal of Medicine and Palliative Care JO - J Med Palliat Care / JOMPAC / jompac PB - MediHealth Academy Yayıncılık WT - DergiPark SN - 2717-7505 SP - 220 EP - 224 VL - 7 IS - 2 LA - en AB - Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. While hepatic steatosis defines the disease, liver fibrosis is the main determinant of prognosis. The fibrosis-4 (FIB-4) score is widely used as a first-line noninvasive tool for fibrosis risk stratification, with a threshold of 1.3 recommended in clinical practice. Quantitative ultrasound techniques, including tissue attenuation imaging (TAI) and tissue scatter imaging (TSI), enable objective assessment of hepatic fat content. This study aimed to investigate the relationship between FIB-4 score and quantitative ultrasound-derived liver fat parameters in patients with MASLD.Methods: This retrospective, single-center study included 196 patients diagnosed with MASLD who underwent quantitative ultrasound liver fat assessment between January 2021 and April 2023. TAI and TSI measurements were obtained under standardized breath-hold conditions with a 1-7 MHz convex transducer. FIB-4 scores were calculated using routine laboratory parameters, and patients were categorized as FIB-4 KW - Metabolic dysfunction-associated steatotic liver disease KW - liver fibrosis KW - fibrosis-4 score KW - ultrasonography KW - hepatic steatosis CR - Younossi ZM, Razavi H, Sherman M, et al. Addressing the high and rising global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): from the growing prevalence to Payors' perspective. Aliment Pharmacol Ther. 2025;61(9):1467-1478. doi:10.1111/apt.70020 CR - Tilg H, Petta S, Stefan N, Targher G. Metabolic dysfunction–associated steatotic liver disease in adults. Jama. 2026;335(2):163-174. doi:10.1001/jama.2025.19615 CR - Sun W, Cui H, Li N, et al. Comparison of FIB-4 index, NAFLD fibrosis score and BARD score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol Res. 2016;46(9):862-870. doi:10.1111/hepr.12647 CR - Henry L, Eberly KE, Shah D, Kumar A, Younossi ZM. Noninvasive tests used in risk stratification of patients with nonalcoholic fatty liver disease. Clin Liver Dis. 2023;27(2):373-395. doi:10.1016/j.cld.2023.01.022 CR - Mozes FE, Lee JA, Vali Y, et al. Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(8):704-713. doi:10.1016/S2468-1253(23)00141-3 CR - Jeon SK, Lee JM, Joo I. Clinical feasibility of quantitative ultrasound imaging for suspected hepatic steatosis: intra- and inter-examiner reliability and correlation with controlled attenuation parameter. Ultrasound Med Biol. 2021;47(3):438-445. doi:10.1016/j.ultrasmedbio. 2020.11.009 CR - Tada T, Kumada T, Toyoda H, et al. Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis. Hepatol Res. 2020;50(2):190-198. doi:10. 1111/hepr.13442 CR - Kumada T, Toyoda H, Ogawa S, et al. Advanced fibrosis leads to overestimation of steatosis with quantitative ultrasound in individuals without hepatic steatosis. Ultrasonography. 2024;43(2):121-131. doi:10. 14366/usg.23194 CR - McPherson S, Hardy T, Dufour JF, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112(5):740-751. doi:10.1038/ajg.2016.453 CR - Vieira Barbosa J, Milligan S, Frick A, et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun. 2022;6(4):765-779. doi:10.1002/hep4.1841 CR - Ferraioli G, Barr RG, Berzigotti A, et al. WFUMB guideline/guidance on liver multiparametric ultrasound: part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography. Ultrasound Med Biol. 2024;50(8):1071-1087. doi:10.1016/j.ultrasmedbio.2024.03.013 CR - Sendur HN, Cerit MN, Fatullayeva T, Erdal ZS, Karabork Kilic AC, Ozhan Oktar S. Do ultrasound based quantitative hepatic fat content measurements have differences between respiratory phases? Acad Radiol. 2023;30(9):1832-1837. doi:10.1016/j.acra.2022.12.021 CR - Liu WY, Huang S, Ji H, et al. From "burnt-out" to "burning-out": capturing liver fat loss in patients with advanced metabolic dysfunction-associated steatotic liver disease from a dynamic perspective. Gastroenterology. 2025;169(2):326-336. doi:10.1053/j.gastro.2025.02.034 CR - Graupera I, Thiele M, Serra-Burriel M, et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin Gastroenterol Hepatol. 2022;20(11):2567-2576e6. doi:10.1016/j.cgh. 2021.12.034 UR - https://doi.org/10.47582/jompac.1871085 L1 - https://dergipark.org.tr/en/download/article-file/5638698 ER -